Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:alternativeName |
gptkb:verubecestat
|
| gptkbp:CASNumber |
1286770-55-5
|
| gptkbp:clinicalTrialOutcome |
did not meet efficacy endpoints
|
| gptkbp:clinicalTrialPhase |
Phase III (terminated)
|
| gptkbp:developedBy |
gptkb:Merck_&_Co.
|
| https://www.w3.org/2000/01/rdf-schema#label |
MK-0826
|
| gptkbp:intendedUse |
Alzheimer's disease treatment
|
| gptkbp:mechanismOfAction |
BACE1 inhibitor
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
development discontinued
|
| gptkbp:bfsParent |
gptkb:ertapenem
|
| gptkbp:bfsLayer |
6
|